At a glance
ClinicalIndex Comparison Record- ✓Advanced cancer diagnosis
- ✓Life expectancy greater than 12 weeks
- ✓Adequate cardiac, pulmonary, hepatic, renal, and hematologic function
- ✓Available high quality vaccine for human use
- ✕Prior gene therapy
- ✕Severe viral infections including HBV, HCV, or HIV
- ✕Known HIV positive status
- ✕Active infectious disease (bacterial, viral, fungal)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anti-cancer Neoantigen mRNA Vaccine to Treat Advanced Solid Tumors: Phase I Clinical Trial
In Brief
A Phase 1 clinical trial evaluating Neoantigen mRNA Vaccine for Solid Tumor, Adult. Currently recruiting, targeting 30 participants across 1 site.
Detailed Summary
The WES and RAN-seq will be performed to identify and verify neoantigens and appropriate mRNA sequences will be verified, manufactured and protected for vaccine production by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the mRNA vaccine for immunotherapy of human cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the mRNA vaccine immunotherapy on human cancers will firstly be evaluated.
Study Details
Timeline
Interventions
Deliver neoantigen mRNA vaccine into patients for anti-ancer therapy.